Franklin Resources Inc. Sells 708,747 Shares of Boston Scientific Corporation $BSX

Franklin Resources Inc. reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 9.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,875,933 shares of the medical equipment provider’s stock after selling 708,747 shares during the quarter. Franklin Resources Inc. owned 0.46% of Boston Scientific worth $671,297,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Magnetar Financial LLC grew its stake in Boston Scientific by 1,101.5% during the third quarter. Magnetar Financial LLC now owns 69,473 shares of the medical equipment provider’s stock worth $6,783,000 after buying an additional 63,691 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Boston Scientific by 4.7% in the 3rd quarter. Van ECK Associates Corp now owns 52,861 shares of the medical equipment provider’s stock valued at $5,161,000 after buying an additional 2,360 shares in the last quarter. FourThought Financial Partners LLC lifted its holdings in shares of Boston Scientific by 1.2% during the 3rd quarter. FourThought Financial Partners LLC now owns 11,772 shares of the medical equipment provider’s stock worth $1,149,000 after acquiring an additional 136 shares during the period. Claret Asset Management Corp lifted its holdings in shares of Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the period. Finally, Capital Research Global Investors boosted its position in shares of Boston Scientific by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 6,633,733 shares of the medical equipment provider’s stock worth $647,650,000 after acquiring an additional 23,940 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on BSX. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Truist Financial reduced their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Citigroup decreased their price target on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday. Morgan Stanley lowered their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, National Bank Financial set a $115.00 price objective on Boston Scientific in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.00.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $69.58 on Thursday. Boston Scientific Corporation has a one year low of $68.19 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market cap of $103.24 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 0.98 and a beta of 0.69. The firm has a 50 day simple moving average of $83.51 and a 200 day simple moving average of $93.81.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target on BSX from $102 to $94 but kept a “buy” rating — signaling the firm still sees meaningful upside even after lowering near-term expectations. This preserves analyst support that can limit downside pressure. Citigroup Lowers PT
• Neutral Sentiment: Unusually large volume of put-option purchases was reported, indicating traders are hedging or speculating on further downside; this raises short‑term volatility but can reflect transient positioning rather than a change in fundamentals. Put Options Flow
• Negative Sentiment: Multiple law firms have filed or announced investigations and class actions against Boston Scientific covering purchases between July 23, 2025 and Feb 3, 2026; plaintiffs allege securities-law violations. A growing wave of litigation increases legal risk, potential discovery costs, and an overhang that often weighs on shares. Bronstein Class Action
• Negative Sentiment: Numerous plaintiff firms (including Rosen, Faruqi, RGRD, Bragar Eagel & Squire, and others) are soliciting lead-plaintiff motions and reminding shareholders of the May 4, 2026 deadline — amplifying publicity and the probability of consolidated litigation. That sustained media/legal attention typically pressures near-term sentiment and can increase legal-cost uncertainty. Deadline Reminder

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.